Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Ischia, J. & So, A. I. The role of heat shock proteins in bladder cancer. Nat. Rev. Urol. 10, 386–395 (2013).
2. Miyata, Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr. Pharm. Des. 11, 1131–1138 (2005).
3. Whitesell, L. et al. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14, 2809–2816 (1997).
4. An, W. G., Schulte, T. W. & Neckers, L. M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11, 355–360 (2000).
5. Workman, P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 3, 297–300 (2003).
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献